Work

1806P Efficacy of niraparib and abiraterone acetate plus prednisone (NIRA+AAP) in homologous recombination repair gene-altered (HRR+) metastatic castration-resistant prostate cancer (mCRPC) by tissue and/or plasma assays in the MAGNITUDE trial

Year: 2023

Type: article

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2023.09.2754

Authors: G. Attard, S.K. Sandhu, D. Rathkopf, E. Castro, M. Saad, M.R. Smith, E.J.J. Small, D. Olmos, A.J.P.D.S. Gomes, G. Roubaud, B. Zurawski, E. Efstathiou, D. Wu, B. Diorio, K. Urtishak, U. Singh, Y. Xu, A. Lopez-Gitlitz, A. del Corral, K.N.N. Chi

Institutions: University College London, Peter MacCallum Cancer Centre, Memorial Sloan Kettering Cancer Center, Hospital Universitario 12 De Octubre, University Malaya Medical Centre, Harvard University, Massachusetts General Hospital, University of California San Francisco Medical Center, UCSF Helen Diller Family Comprehensive Cancer Center, Institut Bergonié, Centrum Onkologii, The University of Texas MD Anderson Cancer Center, Janssen Research & Development (United States), Janssen (United States), BC Cancer Agency

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Pfizer, AstraZeneca, Sanofi, Astellas Pharma

OpenAlex ID: W4387810296

FWCI: 0.177

Cites: 1

Cited by: 1

Related to: 10